Rhopressa for Glaucoma

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: East Coast Institute for Research

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.

Eligibility Criteria

This trial is for adults over 18 with primary open-angle glaucoma or ocular hypertension who've had SLT surgery in the last 90 days. They should have an IOP of 16-28 mmHg and could benefit from further IOP reduction. Women must use birth control if capable of pregnancy. Exclusions include more than one SLT treatment, prior MIGS, current rho kinase inhibitor use, advanced glaucoma, unreliable tonometry readings, active eye infections or inflammation, retinal disease, recent investigational drug/device involvement.

Inclusion Criteria

I have been diagnosed with glaucoma or high eye pressure in both eyes.

I had laser eye surgery in both eyes within the last 3 months.

Mean diurnal intraocular pressure (IOP) of 16 to 28 mmHg at Randomization (V2)

+4 more

Exclusion Criteria

I have had SLT treatment in my eye more than once.

I have had surgery for glaucoma.

I cannot or do not want to stop my current eye pressure medication.

+10 more

Participant Groups

The study tests Rhopressa's effect on intraocular pressure (IOP) in patients post-selective laser trabeculoplasty (SLT). Participants will receive Netarsudil ophthalmic solution 0.02% to see if it can further reduce their IOP compared to artificial tears as a control.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: RhopressaExperimental Treatment1 Intervention

Group II: Artificial TearsPlacebo Group1 Intervention